Initial findings published today in Communications Biology - a Nature portfolio journal - show that 76% of infants in the...
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on...
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company...
MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with...
Winter Park, Florida--(Newsfile Corp. - June 24, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a rising name in the $15.1...
RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start...
PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their...
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across...
Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check...
- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for...
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request...
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025...
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are...
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data...
Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studiesDURHAM, N.C., June...
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is...
Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think TankBROOMFIELD, Colo.,...
Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated...